Table 3.
Randomized trials evaluating hypofractionated intensity-modulated radiation therapy for localized prostate cancer.
| Study | Year | Patient’s Number | PCa Characteristics | Dose (Gy) | ADT | bRFS (Phoenix) | Toxicity | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HYPRO trial | 2016 | 407 vs. 397 | intermediate (26.2%) and high (73.8%) risk | 64.6 in 19 f vs. 78.0 in 39 f | each institutional protocol | 5-year | 80.5% vs. 77.1% | ||||
| CHHiP trial | 2016 | 1074 and 1077 vs. 1065 | low (15.0%), intermediate (73.0%), and high (12.0%) risk | 60 in 20 f or 57 in 19 f vs. 74 in 37 f | 3–6 months | 5-year | 90.6%, 85.9% vs. 88.3% | 2-year grade ≥ 2 GU toxicity | 2%, 1% vs. 1% | 2-year grade ≥ 2 GI toxicity | 3%, 2% vs. 4% |
PCa, prostate cancer; Gy, gray; ADT, androgen deprivation therapy; bRFS, biochemical relapse-free survival; f, fraction; GU, genitourinary; GI, gastrointestinal.